Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

Advanced Prostate Cancer

,

Docetaxel Extends Enzalutamide Effectiveness

,
Docetaxel Extends Enzalutamide Effectiveness

PRESIDE is the first evidence that docetaxel might reduce enzalutamide resistance when given together. It also suggests that triplet therapy may be helpful in men who have already developed castration resistance.

,

Adding A Platinum Drug to Chemotherapy

,
Adding A Platinum Drug to Chemotherapy

The study concluded that adding Carboplatin to cabazitaxel showed improved clinical efficacy compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. Although adverse events were more common with the combination, the treatment was safe and generally well-tolerated.

,

Relugolix - An Oral Lupron Like Drug – On The Horizon

,
Relugolix - An Oral Lupron Like Drug – On The Horizon

Myovant Sciences has developed an alternative gonadotropin-releasing hormone (GnRH) antagonist named relugolix. Their still investigational treatment is an oral (taken by mouth) as opposed to an injectable gonadotropin-releasing hormone (GnRH) antagonist. It has completed a very successful phase III clinical trial called HERO has been submitted to the FDA for approval. We at Cancer ABCs believe relugolix will be approved by the FDA shortly.

, , ,

Phase III HERO Study Meets Primary Efficacy Endpoint in Men with Advanced Prostate Cancer 

, , ,
Phase III HERO Study Meets Primary Efficacy Endpoint in Men with Advanced Prostate Cancer 

If your doctor gave you a choice to take hormone therapy (ADT) using the traditional injection every month, three months, or every six months or to take a daily pill, which would you opt to do? Prepare yourself; you might be facing this question sometime in the later part of 2020! 

,

What Treatment After Zytiga or Xtandi and Chemotherapy Fail?

,

When Xtandi or Zytiga fail what is the best next treatment? We are beginning to better understand how to sequence our advanced prostate cancer treatments, based on the CARD TRIAL using Jevtana after the failure of Zytiga Xtandi and Taxotere might be the superior route.

, , , ,

Apalutamide (Erleada® ) Approved for Metastatic Castrate Sensitive Prostate Cancer

, , , ,

The Food and Drug Administration (FDA) approved apalutamide (ERLEADA), for men with metastatic castration-sensitive prostate cancer (mCSPC).

PROCEED Registry Show Men with Low PSA Scores Have a Median Survival Longer Then Four Years

Results from the PROCEED registry found that men with advanced prostate cancer with low PSA had a median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). A median survival means that one half of the men who participated in the registry lived longer than four years.

,

Using Radioactive Particles to Kill Cells Attached to a ‘Homing Device’ to Seek Out Cancers

,

Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.

An emerging class of drugs are made up of a radioactive particle that can kill cells attached to a ‘homing device’ to seek out cancers by detecting the presence of a target molecule on their surface.

, ,

Germline Mutations As Prognostic Indicators of Castrate Resistance

, ,

In summary, these results demonstrate worse outcomes in men with germline BRCA2 and CHEK2 mutations compared with men without these mutations when treated with standard first-line ADT with LHRH analogs.

,

Evaluating PSMA-Targeted Radionuclide Therapy

,

This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response. 

,

Is There A Role for Testosterone Therapy in the Treatment of Metastatic Prostate Cancer?

,

There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer.  In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone. 

,

ADT With and Without Xtandi in Men with Metastatic Hormone Sensitive Prostate Cancer: The ARCHES Trial

,

After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment. 

,

Darolutamide - Great Results From The ARAMIS Trial For Men With M0 Prostate Cancer

,

The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.  

,

The ENZAMET Study: Adding Enzalutamide to ADT in Metastatic Hormone-Sensitive Prostate Cancer Extends Survival

,

The trial found that 80% of men with metastatic hormone-sensitiveprostate cancer who received enzalutamide (Xtandi) along with standard-of-care treatment (ADT) were alive after three years, compared with just 72% of men who received other nonsteroidal antiandrogens along with standard ADT therapy.

,

An Important Update on the Use of Radium in Combination with Zytiga and Xtandi

,

Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).

, ,

When to Start ADT With A PSA Only Recurrence

, ,

Deferred hormone therapy (ADT) for in relapsing M0 (negative scans) prostate cancer patients is associated with prolonged overall survival (OS) measured from the time of local treatment, comparable to OS with salvage ADT in the contemporary experience.

Gold Guidestar Seal
Gold Transparency 2022